Nelson Vergel
Founder, ExcelMale.com
The US Food and Drug Administration (FDA) has approved Abbott Laboratories' Proclaim XR neurostimulation system for chronic pain patients. The device has a battery life of up to 10 years, the company announced.
The Proclaim XR platform uses the company's proprietary low energy BurstDR stimulation waveform coupled with a low dosing protocol to provide effective pain relief with lower doses of stimulation, which significantly extends the system's battery life.
"Proclaim XR is a major advancement in spinal cord stimulation, and is an evidence-based therapy that is mobile app-based and features upgradeable software. This means patients won't need surgery to benefit from future advances in this technology,"
FDA Clears Novel 'Recharge-Free' Device for Chronic Pain
The Proclaim XR platform uses the company's proprietary low energy BurstDR stimulation waveform coupled with a low dosing protocol to provide effective pain relief with lower doses of stimulation, which significantly extends the system's battery life.
"Proclaim XR is a major advancement in spinal cord stimulation, and is an evidence-based therapy that is mobile app-based and features upgradeable software. This means patients won't need surgery to benefit from future advances in this technology,"
FDA Clears Novel 'Recharge-Free' Device for Chronic Pain
